Ledyard National Bank Has $1.76 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Ledyard National Bank increased its position in Cencora, Inc. (NYSE:COR - Free Report) by 64.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 7,822 shares of the company's stock after purchasing an additional 3,058 shares during the period. Ledyard National Bank's holdings in Cencora were worth $1,757,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Concord Wealth Partners purchased a new position in shares of Cencora during the third quarter valued at $30,000. Householder Group Estate & Retirement Specialist LLC grew its stake in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Cencora in the 3rd quarter valued at about $41,000. Modus Advisors LLC purchased a new stake in shares of Cencora in the fourth quarter worth approximately $54,000. Finally, Carolina Wealth Advisors LLC boosted its holdings in shares of Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company's stock worth $60,000 after purchasing an additional 209 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares of the company's stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock worth $17,790,912 over the last ninety days. Company insiders own 10.80% of the company's stock.

Cencora Stock Performance

Shares of COR stock traded down $1.77 during trading on Monday, reaching $246.11. The company had a trading volume of 767,420 shares, compared to its average volume of 1,462,045. The firm's 50 day simple moving average is $238.94 and its two-hundred day simple moving average is $236.90. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53. The company has a market capitalization of $47.57 billion, a PE ratio of 35.01, a PEG ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio is 31.29%.

Analysts Set New Price Targets

Several research firms have weighed in on COR. Wells Fargo & Company upped their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. Barclays upped their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Finally, Robert W. Baird lifted their price target on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.